Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders
Crossref DOI link: https://doi.org/10.1007/978-3-030-11748-1_19
Published Online: 2019-04-02
Published Print: 2019
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fleming, G. Alexander
Harvey, Brian E.
Text and Data Mining valid from 2019-01-01
Chapter History
First Online: 2 April 2019